Guarize Juliana, Bianchi Fabrizio, Marino Elena, Belloni Elena, Vecchi Manuela, Donghi Stefano, Lo Iacono Giorgio, Casadio Chiara, Cuttano Roberto, Barberis Massimo, Di Fiore Pier Paolo, Petrella Francesco, Spaggiari Lorenzo
Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.
Molecular Medicine Program, European Institute of Oncology, Milan, Italy.
J Thorac Dis. 2018 Jan;10(1):408-415. doi: 10.21037/jtd.2017.12.69.
Novel cancer biomarkers like microRNA (miRNA) are promising tools to gain a better understanding of lung cancer pathology and yield important information to guide therapy. In recent years, new less invasive methods for the diagnosis and staging of NSCLC have become key tools in thoracic oncology and the worldwide spread of endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA). However, appropriate specimen handling is mandatory to achieve adequate results and reproducibility. The aim of this single centre prospective study was to evaluate the feasibility of a complete miRNA expression profile in fresh NSCLC cell lines obtained by EBUS-TBNA.
Patients with proven NSCLC underwent EBUS-TBNA for the diagnosis of suspect lymph node metastasis, and cytological specimens were collected for epithelial cell culture and miRNA expression analysis. To validate the miRNA expression profile, we compared the results from EBUS-TBNA NSCLC specimens with those obtained from formalin-fixed paraffin-embedded (FFPE) mediastinoscopy specimens.
Analysis of the miRNA expression profiles of three independent EBUS-TBNA-derived primary cell lines allowed the screening of 377 different human miRNAs. One hundred and fifty miRNAs were detected in all cell lines. Analysis of the miRNA expression profile in mediastinoscopy specimens showed a strong similarity in the clusters analysed.
The miRNA expression profile is feasible and reliable in EBUS-TBNA specimens. Validation of this protocol in fresh cytological specimens represents an effective and reproducible method to correlate translational and clinical research.
新型癌症生物标志物如微小RNA(miRNA)是有助于更好地理解肺癌病理学并提供重要治疗指导信息的有前景的工具。近年来,非小细胞肺癌(NSCLC)诊断和分期的新的微创方法已成为胸科肿瘤学的关键工具以及支气管内超声引导下经支气管针吸活检术(EBUS-TBNA)在全球的广泛应用。然而,恰当的标本处理对于获得充分的结果和可重复性是必不可少的。本单中心前瞻性研究的目的是评估通过EBUS-TBNA获得的新鲜NSCLC细胞系中完整miRNA表达谱的可行性。
经证实患有NSCLC的患者接受EBUS-TBNA以诊断可疑的淋巴结转移,并收集细胞学标本用于上皮细胞培养和miRNA表达分析。为验证miRNA表达谱,我们将EBUS-TBNA NSCLC标本的结果与从福尔马林固定石蜡包埋(FFPE)纵隔镜检查标本获得的结果进行了比较。
对三个独立的源自EBUS-TBNA的原代细胞系的miRNA表达谱分析允许筛选377种不同的人类miRNA。在所有细胞系中检测到150种miRNA。纵隔镜检查标本中miRNA表达谱分析显示在所分析的簇中有很强的相似性。
miRNA表达谱在EBUS-TBNA标本中是可行且可靠的。在新鲜细胞学标本中验证该方案代表了一种将转化研究与临床研究相关联的有效且可重复的方法。